2023 World Conference on Lung Cancer (Posters)-EP11.03. Real World Outcomes after Chemotherapy and Immunotherapy in Patients with Metastatic Non-Small Cell Lung Cancer in Europe

EP11.03. Real World Outcomes after Chemotherapy and Immunotherapy in Patients with Metastatic Non-Small Cell Lung Cancer in Europe - PDF(Abstract)

Back to course

Pdf Summary

A retrospective study was conducted to assess the real-world outcomes of chemotherapy and immunotherapy in patients with metastatic non-small cell lung cancer (mNSCLC) in Europe. The study included patients who had disease progression on anti-PD-1/anti-PD-L1 immunotherapy and platinum-doublet chemotherapy. Medical chart data from patients in France, Germany, and the United Kingdom were collected and analyzed.<br /><br />The study included 218 patients with Stage IV squamous/non-squamous mNSCLC. The majority of patients had de novo mNSCLC and an ECOG performance status of 0-1. The most common sites of metastasis were the liver and brain. The majority of patients were male and current/former smokers. The median follow-up from the index date was 8 months.<br /><br />Among the eligible patients, 95.9% had disease progression on anti-PD-1/anti-PD-L1 and platinum-doublet chemotherapy in the first line of treatment. Most patients received non-platinum chemotherapy as subsequent treatment. The median overall survival from the index date was 8.2 months, and the median time-to-treatment discontinuation was 4.2 months.<br /><br />The study found that the treatment regimens for mNSCLC patients with disease progression on anti-PD-1/anti-PD-L1 and platinum-doublet chemotherapy were heterogenous. The clinical outcomes were poor, indicating a need for more effective therapies for patients who are refractory to anti-PD-1/anti-PD-L1 and platinum-doublet chemotherapy.<br /><br />In summary, this study evaluated the real-world outcomes of chemotherapy and immunotherapy in patients with metastatic non-small cell lung cancer in Europe. The findings highlight the need for improved therapies for patients who do not respond to standard treatments.

Asset Subtitle

Ticiana Leal

Meta Tag

Speaker Ticiana Leal

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

retrospective study

real-world outcomes

chemotherapy

immunotherapy

metastatic non-small cell lung cancer

mNSCLC

Europe

disease progression

overall survival

effective therapies